Infectious diseases caused by organisms (bacteria, viruses, fungi, etc.) are among the top leading causes of death. The emergence of new bacteria and new viruses, such as SARS-Cov-2, has been identified as a threat to global public health with high economic and social impacts. Although SARS-CoV-2 primarily targets the respiratory system, other lasting health effects, such as heart complications, neurological symptoms, were also observed from COVID-19 patients.
Despite the development of antibiotics, drug resistance threatens the efficacy of all current antimicrobial agents. In addition, the unclear pathogenesis and host-related adverse reactions hinder the discovery of novel anti-infectious therapeutics development.
The rapid development and application of the mRNA vaccine against COVID-19 opened a new era in vaccinology. Yet the large need for global vaccination and limited accessibility in developing countries is still beyond the current paradigm of the vaccine approach.
There is an urgent need for more basic science and to identify affordable and effective treatments to combat infections. We would like to advance the current theoretical aspects of anti-infectious drug discovery in this research topic. The mechanistic, basic, translational, and clinical research aiming at identifying preventive and therapeutic strategies are of paramount importance. Another goal is to study the neurologic manifestations of patients with COVID-19. In addition, new vaccine and immunization approaches would be appreciated for global public health to stop and prevent the pandemic.
We welcome original research articles and reviews that cover areas including but not limited to:
• Investigation of novel therapeutic and pharmacological approaches (natural products/synthetic small organic molecules/ herbal medicines and their metabolites, etc.)
• New macromolecule therapeutics, primarily (but not exclusively) antibodies and antibody-drug conjugates
• Identification of potential drug targets
• Basic experimental research in the immune pathophysiology relating to infection
• COVID-19 related treatment
• Nanomedicine and materials for infection treatment
• Unveiling the cellular and molecular processes are affected in the brains of patients with COVID-19.
Infectious diseases caused by organisms (bacteria, viruses, fungi, etc.) are among the top leading causes of death. The emergence of new bacteria and new viruses, such as SARS-Cov-2, has been identified as a threat to global public health with high economic and social impacts. Although SARS-CoV-2 primarily targets the respiratory system, other lasting health effects, such as heart complications, neurological symptoms, were also observed from COVID-19 patients.
Despite the development of antibiotics, drug resistance threatens the efficacy of all current antimicrobial agents. In addition, the unclear pathogenesis and host-related adverse reactions hinder the discovery of novel anti-infectious therapeutics development.
The rapid development and application of the mRNA vaccine against COVID-19 opened a new era in vaccinology. Yet the large need for global vaccination and limited accessibility in developing countries is still beyond the current paradigm of the vaccine approach.
There is an urgent need for more basic science and to identify affordable and effective treatments to combat infections. We would like to advance the current theoretical aspects of anti-infectious drug discovery in this research topic. The mechanistic, basic, translational, and clinical research aiming at identifying preventive and therapeutic strategies are of paramount importance. Another goal is to study the neurologic manifestations of patients with COVID-19. In addition, new vaccine and immunization approaches would be appreciated for global public health to stop and prevent the pandemic.
We welcome original research articles and reviews that cover areas including but not limited to:
• Investigation of novel therapeutic and pharmacological approaches (natural products/synthetic small organic molecules/ herbal medicines and their metabolites, etc.)
• New macromolecule therapeutics, primarily (but not exclusively) antibodies and antibody-drug conjugates
• Identification of potential drug targets
• Basic experimental research in the immune pathophysiology relating to infection
• COVID-19 related treatment
• Nanomedicine and materials for infection treatment
• Unveiling the cellular and molecular processes are affected in the brains of patients with COVID-19.
